GlassScriptPhysician profile
Edward Alan Maltbie
NPI 1578787495
$2,856.19
in general payments reported to CMS, 2019-2025
24 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $277 · 2021: $572 · 2022: $614 · 2023: $247 · 2024: $454 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $992.99 | 2019-2025 | |
| Janssen Biotech, INC. | $293.43 | 2020-2024 | Stelara |
| Celgene Corporation | $238.49 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.57 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $179.92 | 2019-2024 | Entyvio |
| Ardelyx, INC. | $159.94 | 2022-2025 | Ibsrela |
| Pfizer INC. | $141.43 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $111.76 | 2019-2024 | Rebyota |
| Genzyme Corporation | $111.37 | 2024-2025 | |
| Gilead Sciences, INC. | $93.51 | 2019-2025 | |
| Allergan, INC. | $45.10 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.43 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $38.10 | 2020-2022 | |
| Amgen INC. | $36.50 | 2022-2023 | Amjevita, Avsola |
| Mallinckrodt Hospital Products INC. | $32.22 | 2022-2023 | Terlivaz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $21.74 | 2021 | |
| Redhill Biopharma INC. | $20.27 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.88 | 2023 | Voquezna |
| Olympus America INC. | $19.83 | 2019 | |
| Apollo Endosurgery US INC | $19.16 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.69 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $17.42 | 2019 | |
| Braintree Laboratories, INC. | $15.44 | 2024 | Suflave, Sutab |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Maltbie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.